March 22, 2021 Bio/Pharma/CRO Informatics & Software Lab Top-10 M&A, Partnerships Mass Spectrometry

Thermo Fisher Scientific Collaborates with Protein Metrics to Optimize Mass Spectrometry Data Analysis for Biopharmaceutical and Proteomics Applications

Thermo Fisher Scientific Collaborates with Protein Metrics to Optimize Mass Spectrometry Data Analysis for Biopharmaceutical and Proteomics Applications Protein Metrics’ software solutions complement Thermo Fisher’s mass spectrometry systems to facilitate precise, reliable data processing and drive innovation GERMERING, Germany, March 22, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Protein Metrics,... Read more

March 22, 2021 Bio/Pharma/CRO

Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning

First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care Treating lung cancer early, before it has spread, may help prevent the disease from returning and therefore provide the best opportunity for a cure Data will be submitted to... Read more

March 17, 2021 Bio/Pharma/CRO Lab Top-10

PerkinElmer Further Expands Industry-Leading Signals™ Informatics Capabilities in Biologics Drug Discovery

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community. With... Read more

March 11, 2021 Bio/Pharma/CRO Microscopy

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia

The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone Roche will submit the REMDACTA results to a peer-reviewed journal Basel, 11 March 2021 – Roche (SIX: RO, ROG; OTCQX:... Read more

February 26, 2021 Bio/Pharma/CRO Lab Top-10 PAI Top-10

Thermo Fisher Scientific Completes Acquisition of Mesa Biotech

WALTHAM, Mass., Feb. 26, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has completed its previously announced acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company. “Mesa Biotech is an important part of our strategy to expand the benefits of molecular diagnostics at... Read more

February 12, 2021 Bio/Pharma/CRO Product Launch

New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients

Across four studies in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), approximately half of people receiving faricimab could be treated every four months in the first year Approximately three-quarters of people receiving faricimab could be treated every three months or longer in the first year Faricimab showed rapid and consistent improvements in... Read more

January 26, 2021 Atomic Spectroscopy Bio/Pharma/CRO Product Launch

Digital innovation is unlocking new pharmaceutical and chemical research horizons, according to MIT Technology Review Insights

Mailing addressesCorrespondence should be mailed to:ComputershareP.O. Box 505000Louisville, KY 40233 Overnight correspondence should be sent to:Computershare462 South 4th Street, Suite 1600Louisville, KY 40202 Shareholder website www.computershare.com/investorShareholder online inquirieswww-us.computershare.com/investor/Contact Read more

January 25, 2021 Bio/Pharma/CRO

Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration

Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatment Nearly half of people were treated with faricimab every 16 weeks during the first year – the first time this level of... Read more

January 19, 2021 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech WALTHAM, Mass., Jan. 19, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash.... Read more

December 21, 2020 Acad, Gov/Utilities Bio/Pharma/CRO

Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness

Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies More than half of participants in the faricimab personalised dosing arms had extended time between treatments to 16 weeks at year one – the first... Read more